SCREENING FOR NASOPHARYNGEAL CARCINOMA WITH AN ELISA USING THE EPSTEIN-BARR-VIRUS NUCLEAR ANTIGEN, EBNA-1 - A COMPLEMENTARY TEST TO THE IGA/VCA IMMUNOFLUORESCENCE ASSAY

被引：12

作者：

CHENG, HM ^{[1
]}

FOONG, YT ^{[1
]}

MATHEW, A ^{[1
]}

SAM, CK ^{[1
]}

DILLNER, J ^{[1
]}

PRASAD, U ^{[1
]}

机构：

[1] KAROLINSKA INST,DEPT VIROL,S-10401 STOCKHOLM 60,SWEDEN

来源：

JOURNAL OF VIROLOGICAL METHODS | 1993年 / 42卷 / 01期

关键词：

EBNA-1; PEPTIDE; NASOPHARYNGEAL CARCINOMA;

D O I：

10.1016/0166-0934(93)90175-Q

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

An ELISA using the Epstein-Barr virus nuclear antigen 1 (EBNA 1) was found to detect selectively specific IgA in sera from patients with nasopharyngeal carcinoma (NPC). The antigen, p107, was a 20-amino acid synthetic peptide, representing a major epitope of EBNA 1. 267/294 (90.8%) of NPC patients had IgA antibodies to p107 but in normal individuals, only 41/577 (7.1%) had IgA/p107. In sera from patients with other cancers, 11/77 (14.3%) had IgA/p107 reactivity. 124 IgA/VCA positive and 86 IgA/VCA negative NPC sera were also tested for IgA/p107 binding in ELISA. The majority of IgA/VCA positive sera (117) also contained IgA/p107 antibodies. Of interest was the detection of 74/86 IgA/p107 reactive sera in the IgA/VCA negative group. The results suggest that the IgA/p107 ELISA could become a useful, complementary screening assay to the IgA/VCA immunofluorescence test for detection of NPC.

引用

页码：45 / 52

页数：8

共 17 条

[11] EPSTEIN-BARR VIRUS-SPECIFIC IGA SERUM ANTIBODIES AS AN OUTSTANDING FEATURE OF NASOPHARYNGEAL CARCINOMA [J].

HENLE, G ;

HENLE, W .

INTERNATIONAL JOURNAL OF CANCER, 1976, 17 (01) :1-7

[12]

HENLE W, 1985, ADV VIRAL ONCOL, V5, P201

[13]

MORIARTY AM, 1985, SCIENCE, V227, P427

[14]

SAM CK, 1989, EUR J SURG ONCOL, V11, P17

[15]

SUTCLIFFE JG, 1980, NATURE, V287, P802

[16]

THOE SYS, 1989, J MED VIROL, V29, P311

[17]

THORLEYLAWSON DA, 1988, SEMIN HEMATOL, V25, P247

← 1 2 →